Suppr超能文献

手术微波消融治疗根治性肝切除术后复发性肝细胞癌的疗效。

Efficacy of surgical microwave ablation for recurrent hepatocellular carcinoma after curative hepatectomy.

机构信息

Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

出版信息

HPB (Oxford). 2020 Mar;22(3):461-469. doi: 10.1016/j.hpb.2019.08.001. Epub 2019 Aug 28.

Abstract

BACKGROUND

Little evidence exists regarding postrecurrence survival after microwave ablation for recurrent hepatocellular carcinoma (HCC) after curative hepatectomy; we aimed to evaluate the feasibility of surgical microwave ablation.

METHODS

In this retrospective review, we enrolled patients who underwent curative hepatectomy for primary HCC in our department and had intrahepatic recurrence. We analyzed overall survival according to treatment modality to clarify the prognostic factors for survival.

RESULTS

Of 257 patients, 119 had intrahepatic recurrence. Three patients underwent repeat hepatectomy; 75 patients underwent surgical microwave ablation, and 34 patients underwent transcatheter arterial chemoembolization or hepatic arterial infusion chemotherapy. The median postrecurrence survival time and 5-year postrecurrence survival after surgical microwave ablation were 37.4 months and 55.4%, respectively. The major complication rate (Clavien-Dindo classification IIIa or above) after surgical microwave ablation was 5.3% with no mortality. Multivariate analysis showed that microvascular invasion at primary tumors, and recurrent tumors within 3 cm and 3 nodules were independent prognostic factors for overall survival after surgical microwave ablation for recurrent HCC.

CONCLUSION

Our results suggested that surgical microwave ablation is safe and feasible for recurrent intrahepatic HCC after curative hepatectomy. Close follow-up and further curative treatment could be important for improving postrecurrence survival.

摘要

背景

对于根治性肝切除术后复发性肝细胞癌(HCC)微波消融后的复发后生存情况,证据有限;我们旨在评估手术微波消融的可行性。

方法

在这项回顾性研究中,我们纳入了在我科接受根治性肝切除术治疗原发性 HCC 并发生肝内复发的患者。我们根据治疗方式分析总生存率,以明确生存的预后因素。

结果

在 257 例患者中,有 119 例发生了肝内复发。3 例患者接受了再次肝切除术;75 例患者接受了手术微波消融,34 例患者接受了经导管动脉化疗栓塞或肝动脉灌注化疗。手术微波消融后复发后的中位生存时间和 5 年复发后生存率分别为 37.4 个月和 55.4%。手术微波消融后的主要并发症发生率(Clavien-Dindo 分级 IIIa 或以上)为 5.3%,无死亡病例。多因素分析显示,肿瘤微血管侵犯、复发肿瘤<3cm 和 3 个结节是手术微波消融治疗复发性 HCC 后总生存率的独立预后因素。

结论

我们的结果表明,对于根治性肝切除术后复发性肝内 HCC,手术微波消融是安全可行的。密切随访和进一步的根治性治疗对于提高复发后生存可能是重要的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验